奥希替尼联合培美曲塞、顺铂、血管生成抑制剂治疗EGFR突变阳性晚期非小细胞肺癌的临床效果分析
Analysis of the Clinical Efficacy of Osimertinib Combined with Pemetrexed,Cisplatin,and Angiogenesis Inhibitors in Treating EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
俞强1
作者信息
- 1. 南阳豫西健和医院 肿瘤内科,河南 南阳 474500
- 折叠
摘要
目的 分析奥希替尼联合培美曲塞、顺铂、血管生成抑制剂治疗应用表皮生长因子受体(EGFR)突变阳性晚期非小细胞肺癌的临床价值.方法 选择 2020 年 2 月至 2023 年 12 月南阳豫西健和医院收入的EGFR突变阳性晚期非小细胞肺癌患者 62 例进行回顾性分析,依据治疗方式的不同分为A组(奥希替尼+培美曲塞+顺铂)与B组(奥希替尼+培美曲塞+顺铂+血管生成抑制剂),各 31 例,比较两组患者治疗效果、血管生成指标、T淋巴细胞亚群、血清肿瘤标志物及安全性进行组间比较.结果 B组患者治疗有效率(45.16%)、疾病控制率(70.97%)均高于A组(19.35%、38.71%),差异有统计学意义(P＜0.05);B组患者治疗后CD4+、CD4+/CD8+均高于A组,且CD8+、血管内皮生长因子(VEGF)、细胞质胸苷激酶(TKl)水平均低于A组,差异有统计学意义(P＜0.05);两组患者不良反应发生率比较,差异无统计学意义(P＞0.05).结论 EGFR突变阳性晚期非小细胞肺癌采取奥希替尼+培美曲塞+顺铂+血管生成抑制剂药物治疗效果显著,具有可行性.该治疗方案不仅能有效地抑制肿瘤细胞血管生成的能力,还可以加强机体的免疫功能,且有较高的用药安全性.
Abstract
Objective To analyze the clinical value of osimertinib combined with pemetrexed,cisplatin,and angiogenesis inhibitors in the treatment of advanced non-small cell lung cancer(NSCLC)with positive epidermal growth factor receptor(EGFR)mutations.Methods A retrospective analysis was conducted on 62 patients with EGFR mutation-positive advanced NSCLC admitted to Nanyang Yuxi Jianhe Hospital from February 2020 to December 2023.Based on different treatment regimens,patients were divided into Group A(osimertinib+pemetrexed+cisplatin)and Group B(osimertinib+pemetrexed+cisplatin+angiogenesis inhibitors),with 31 patients in each group.The treatment outcomes,angiogenesis indicators,T lymphocyte subsets,serum tumor markers,and safety were compared between the two groups.Results The treatment efficacy rate(45.16%)and disease control rate(70.97%)in Group B were significantly higher than those in Group A(19.35%and 38.71%,respectively)(P＜0.05).After treatment,levels of CD4+and the CD4+/CD8+ratio in Group B were higher than those in Group A,while CD8+,vascular endothelial growth factor(VEGF),and thymidine kinase(TKl)levels were lower in Group B than in Group A,with significant differences(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion The treatment regimen of osimertinib combined with pemetrexed,cisplatin,and angiogenesis inhibitors is effective and feasible for patients with EGFR mutation-positive advanced NSCLC.This combination not only effectively inhibits the tumor cells'ability to generate blood vessels but also enhances immune function with a high level of safety in medication use.
关键词
奥希替尼/培美曲塞/顺铂/非小细胞肺癌/表皮生长因子受体Key words
Osimertinib/Pemetrexed/Cisplatin/non-small cell lung cancer/epidermal growth factor receptor引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据